SANTA ANA, CA — May 11, 2021 — FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the company has established a reputation as an innovator and leader in providing cell culture solutions for the life science and medical markets.
From its inception in the 1970s as a fetal bovine serum supplier, the company has continuously provided pioneering cell culture solutions. In the 1980s it revolutionized embryo culture with commercially available media for in vitro fertilization (IVF) clinics worldwide. In the 1990s, the company brought chemically defined media to biotherapeutic manufacturers. Most recently FUJIFILM Irvine Scientific launched products which better support cell culture-based vaccine production, and advanced cell and gene therapy applications. Since its acquisition by FUJIFILM Corporation, the company has expanded its global reach and manufacturing capacity more rapidly. This expansion positions the company to meet the growing needs of life science and medical customers.
“We have reflected on our trailblazing history and many contributions over the last five decades. Our 50th year coincided with unprecedented challenges from the COVID-19 pandemic,” said Yutaka Yamaguchi, CEO and chairman of the board, FUJIFILM Irvine Scientific. “We are grateful for the dedication and commitment shown by our employees to uphold our standards of delivering the highest quality products and service under these difficult conditions. We are also humbled by the extraordinary efforts of the community we serve in the fight against the virus and honored that our customers trust FUJIFILM Irvine Scientific to provide the critical cell culture media needed to manufacture lifesaving therapies and vaccines, and to support medical applications. We are inspired to continue our mission to improve health through innovation, partnership, and service for the next 50 years.”
Tim Mullane, president and COO, FUJIFILM Irvine Scientific, commented: “Our history in medical and life science applications includes many firsts and cell culture improvements. These advances have allowed our customers to achieve better and more consistent results from their cell culture, which in turn has fueled tremendous company growth. The pandemic has required us to accelerate plans for production capacity expansion. We doubled our capacity in California and expect production from our Netherlands facility before the end of 2021. During this pronounced demand for COVID-19 therapies and vaccines our entire organization is motivated to support programs, such as collaborations with the US government, and others combating the pandemic.”